|
| 36504141 | Trends in Stage I Lung Cancer. | Clin Lung Cancer | 2023 |
| 37783809 | Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer. | NPJ Precis Oncol | 2023 |
| 37677122 | Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). | JCO Precis Oncol | 2023 |
| 36993328 | Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer. | Res Sq | 2023 |
| 36623230 | High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538. | J Clin Oncol | 2023 |
| 36917417 | Trajectories of participation in daily life among individuals newly diagnosed with cancer: A 5-month longitudinal study. | Support Care Cancer | 2023 |
| 34985935 | Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer. | J Clin Oncol | 2022 |
| 35419282 | Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer. | Front Oncol | 2022 |
| 36814898 | Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma. | Neurooncol Adv | 2022 |
| 36179540 | Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors. | Lung Cancer | 2022 |
| 35226229 | Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors. | Invest New Drugs | 2022 |
| 35225130 | COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience. | Leuk Lymphoma | 2022 |
| 35074432 | Phase I Study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer. | Int J Radiat Oncol Biol Phys | 2022 |
| 35247086 | Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors. | Cancer Chemother Pharmacol | 2022 |
| 35150356 | Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors. | Invest New Drugs | 2022 |
| 33417483 | Adjuvant Therapy With EGFR Tyrosine Kinase Inhibitors: Tempering Great Expectations With Realism. | J Clin Oncol | 2021 |
| 33928209 | Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial. | JCO Precis Oncol | 2021 |
| 34902832 | Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2021 |
| 34591593 | Genomic Profiling of Lung Adenocarcinoma in Never-Smokers. | J Clin Oncol | 2021 |
| 34422335 | A phase II study of everolimus in patients with advanced solid malignancies with <i>TSC1, TSC2, NF1, NF2</i> or <i>STK11</i> mutations. | J Thorac Dis | 2021 |
| 34256279 | Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies. | Eur J Cancer | 2021 |
| 34354225 | A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. | NPJ Precis Oncol | 2021 |
| 33221175 | A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). | Clin Lung Cancer | 2021 |
| 33159216 | A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors. | Cancer Chemother Pharmacol | 2021 |
| 32271363 | The Mystic Role of Tumor Mutational Burden in Selecting Patients With Lung Cancer for First-Line Immunotherapy. | JAMA Oncol | 2020 |
| 33282370 | Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer. | J Thorac Dis | 2020 |
| 32771088 | Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. | Lancet Oncol | 2020 |
| 32880608 | Demystifying the Role of Tumor Mutational Burden for Immunotherapy Selection-Reply. | JAMA Oncol | 2020 |
| 32173247 | Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy. | Clin Lung Cancer | 2020 |
| 30933354 | Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapy. | Cancer | 2019 |
| 31302234 | SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). | J Thorac Oncol | 2019 |
| 31300452 | Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations. | Clin Cancer Res | 2019 |
| 31231122 | RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer. | Br J Cancer | 2019 |
| 31446141 | Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. | J Thorac Oncol | 2019 |
| 26669741 | Immunogenicity of Influenza Vaccination in Patients With Cancer. | Am J Clin Oncol | 2018 |
| 29906251 | Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. | J Clin Oncol | 2018 |
| 30224629 | Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. | Nat Commun | 2018 |
| 30413381 | Lorlatinib: a new-generation drug for ALK-positive NSCLC. | Lancet Oncol | 2018 |
| 29526531 | Non-small-cell Lung Cancer With Brain Metastasis at Presentation. | Clin Lung Cancer | 2018 |
| 29410127 | Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-Small Cell Lung Cancer. | J Thorac Oncol | 2018 |
| 29599410 | Clinical Utility of Cell-Free DNA for the Detection of <i>ALK</i> Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. | Clin Cancer Res | 2018 |
| 29681434 | A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation. | Clin Lung Cancer | 2018 |
| 29563138 | Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. | Clin Cancer Res | 2018 |
| 29204695 | Percutaneous Image-Guided Ablation in the Treatment of Osseous Metastases from Non-small Cell Lung Cancer. | Cardiovasc Intervent Radiol | 2018 |
| 29217530 | The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). | Clin Cancer Res | 2018 |
| 26359696 | Brain Metastases at Presentation in Patients With Non-Small Cell Lung Cancer. | Am J Clin Oncol | 2018 |
| 27912831 | Systemic Treatment of Brain Metastases. | Hematol Oncol Clin North Am | 2017 |
| 29113403 | A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients. | Oncotarget | 2017 |
| 28579387 | Treatment advances in small cell lung cancer (SCLC). | Pharmacol Ther | 2017 |
| 26780363 | A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer. | Chemotherapy | 2016 |